Pancreatic Cancer Trial Findings Will Be Presented Soon
New results from a Phase 2 study evaluating an experimental immunotherapy will be shared at an upcoming conference.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Should pharmaceutical companies focus resources on developing standardized off-the-shelf cancer immunotherapies?
Elicio Therapeutics will present data from its AMPLIFY-7P study on October 23, 2026, at the ESMO Congress in Madrid. The trial investigated a targeted immunotherapy for patients with pancreatic ductal adenocarcinoma.
Why it matters
Pancreatic cancer remains a difficult-to-treat malignancy, and the forthcoming analysis will provide additional insights into the potential clinical role of the ELI-002 7P immunotherapy. These findings are intended to help define the development strategy for future Phase 3 clinical trials.
The Phase 2 AMPLIFY-7P trial enrolled 144 patients with mKRAS-driven pancreatic ductal adenocarcinoma to evaluate an experimental immunotherapy versus observation. The study did not meet its pre-specified primary disease-free survival endpoint in the intent-to-treat population.
The players
Elicio Therapeutics
A biotechnology company focused on developing immunotherapies for cancer, including lymph-node-targeted treatments.
The details
The experimental treatment, ELI-002 7P, is designed as a lymph-node-targeted amphiphile immunotherapy. It works by specifically targeting mKRAS, a mutation found in approximately 25% of solid tumors, to trigger an immune response against cancer cells. The upcoming presentation will offer deeper analysis into the potential clinical benefit of this approach in resected pancreatic ductal adenocarcinoma.
Timeline
October 23, 2026: Late-breaking study results will be presented at the ESMO Congress.
October 23-27, 2026: The ESMO Congress 2026 event will take place in Madrid, Spain.
Health Landscape
The presentation of these results follows the standard pattern of scientific disclosure at the ESMO Congress to update the global oncology community on pipeline development. It sits within a broader landscape of efforts to target KRAS mutations, which drive about 25% of all solid tumors.
This news concerns the development of new treatments for pancreatic cancer and does not change current care standards. Patients interested in learning more about clinical trials should discuss their specific situation and eligibility with their oncologist.
The takeaway
Advancements in targeted immunotherapy continue to be a major focus for research in pancreatic cancer. Patients managing this condition should consult their oncology team to monitor for updates in treatment protocols or clinical trial opportunities that may become relevant in the future.
What happens next
A late-breaking abstract will be available on the ESMO Congress 2026 website starting October 23, 2026, and a webcast of the session will be posted on the ESMO Virtual Platform within 12 hours of the presentation.
Further reading
For more on the current status of research for this condition, visit the Cancer section.
More information
For further information about the company's research, visit the Elicio Therapeutics company website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical companies focus resources on developing standardized off-the-shelf cancer immunotherapies?
